N 66 (n=137/207), 64 (n=133/207), and 18 (n=39/207) of individuals, respectively, getting sorafenib, and
Chemexpress N 66 (n=137/207), 64 (n=133/207), and 18 (n=39/207) of patients, respectively, getting sorafenib, and in 25 (n=54/209), 9 (n=19/209), and 3 (n=8/209) of sufferers, respectively, receiving placebo. HFSR was by…